Gala­pa­gos posts a safe­ty win for fil­go­tinib, but is it too lit­tle, too late?; Bio-Techne inks $320M mol­e­c­u­lar di­ag­nos­tics buy­out

Once a promis­ing $725 mil­lion play in im­munol­o­gy, Gilead’s big bet on fil­go­tinib ef­fec­tive­ly dis­in­te­grat­ed in De­cem­ber when the drug­mak­er re­worked its part­ner­ship with Gala­pa­gos. Now, Gala­pa­gos is sport­ing safe­ty da­ta that will come as a re­lief — but will it make a dif­fer­ence on fil­go­tinib’s chances in the US?

In a study de­signed to com­pare fil­go­tinib’s ef­fect on sperm count with place­bo, Gala­pa­gos’ JAK in­hibitor saw few­er pa­tients post a 50% or more re­duc­tion in sperm con­cen­tra­tion af­ter 13 weeks of treat­ment, ac­cord­ing to da­ta from the MAN­TA and MAN­TA-RAy stud­ies un­veiled Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.